Biodesix (NASDAQ:BDSX) Stock Gets Price Target Cut from HC Wainwright

Biodesix (NASDAQ:BDSX) had its price objective trimmed by HC Wainwright from $38.00 to $34.00 in a research note published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Biodesix’s Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($3.13) EPS, Q1 2027 earnings at ($0.75) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($2.18) EPS.

A number of other brokerages have also weighed in on BDSX. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Canaccord Genuity Group increased their target price on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, TD Cowen reissued a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

Biodesix Price Performance

Shares of NASDAQ:BDSX opened at $10.12 on Monday. Biodesix has a one year low of $5.26 and a one year high of $31.97. The company has a debt-to-equity ratio of 5.43, a current ratio of 2.96 and a quick ratio of 2.85. The company has a market cap of $112.22 million, a price-to-earnings ratio of -3.67 and a beta of 0.65. The firm has a 50 day simple moving average of $24.57 and a 200 day simple moving average of $18.88.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.75). The firm had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.48 million. Biodesix had a negative net margin of 25.74% and a negative return on equity of 442.34%. Research analysts predict that Biodesix will post -2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biodesix

Large investors have recently modified their holdings of the business. AIGH Capital Management LLC lifted its holdings in shares of Biodesix by 1.1% during the third quarter. AIGH Capital Management LLC now owns 686,021 shares of the company’s stock worth $20,464,000 after purchasing an additional 7,693 shares during the period. Walleye Capital LLC acquired a new stake in Biodesix in the second quarter valued at $1,679,000. GSA Capital Partners LLP acquired a new stake in Biodesix in the second quarter valued at $1,060,000. Stempoint Capital LP acquired a new stake in Biodesix in the first quarter valued at $1,015,000. Finally, BlackRock Inc. bought a new position in Biodesix during the 2nd quarter worth $970,000. Institutional investors own 20.96% of the company’s stock.

Key Biodesix News

These are some of the BDSX news items that stood out recently:

• Positive Sentiment: HC Wainwright kept its Buy rating and $34 target, suggesting the analyst still sees potential upside despite lowering its forecasts. HC Wainwright Has Lowered Expectations for Biodesix
• Neutral Sentiment: Biodesix announced new data and a strategy focused on minimal residual disease (MRD) at a molecular pathology meeting. The article headline offers no details about the data or its potential commercial impact. Biodesix announces new data and showcases MRD strategy
• Negative Sentiment: HC Wainwright cut its loss-per-share estimates across 2026 and 2027. It now forecasts losses of $0.86 for Q4 2026 and $3.13 for FY2026, versus prior estimates of $0.47 and $2.72; its FY2027 loss estimate rose from $1.57 to $2.18 per share. The revisions point to weaker expected profitability, despite the retained Buy rating and target.

About Biodesix

Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions. Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.